Nektar Therapeutics
Statements
Cash Flow
Nektar Therapeutics (NKTR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -76 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27 | -52 | -35 | -59 | 93 | -80 | -52 | 960 | -71 | -118 | -81 | -54 | -69 | -125 | -78 | -84 | -53 | -99 | -77 | -83 | -101 | -152 | -88 | -75 | -83 | -58 | -52 | -52 | -42 | -47 | -48 | -38 | -44 | -46 | -49 | -46 | -49 | -65 | -44 | -76 | -234 | |
| 3.9 | 3.8 | 4.0 | 4.3 | 3.8 | 2.7 | 2.5 | 2.6 | 2.7 | 3.1 | 3.1 | 3.1 | 3.5 | 3.6 | 4.5 | 3.2 | 3.2 | 3.2 | 3.5 | 3.5 | 3.6 | 3.4 | 3.7 | 3.4 | 2.7 | 2.4 | 2.3 | 2.2 | 1.7 | 1.7 | 1.6 | 1.5 | 1.0 | 0.3 | 0.4 | -0.7 | 0.2 | -0.4 | 0.2 | 0.2 | 0.1 | |
| 6.2 | 7.1 | 8.2 | 8.1 | 8.8 | 11 | 20 | 21 | 23 | 24 | 25 | 25 | 25 | 25 | 25 | 23 | 24 | 22 | 24 | 24 | 25 | 22 | 21 | 11 | 13 | 13 | 10 | 8.0 | 8.1 | 7.3 | 6.0 | 5.4 | 5.4 | 4.8 | 3.9 | 3.5 | 3.1 | 2.2 | 3.4 | 3.4 | 12 | |
| 2.4 | 4.0 | 5.3 | 5.6 | 5.0 | 8.2 | 18 | 13 | 16 | 30 | 19 | 18 | 18 | 34 | 21 | 23 | 24 | 8.5 | 25 | 24 | 29 | 43 | -16 | 59 | 1.3 | 6.9 | 84 | 6.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 9.5 | -18 | 20 | -8.5 | 23 | -72 | 23 | -27 | 6.5 | -41 | 16 | 35 | 8.9 | -38 | 15 | -30 | 29 | 2.9 | 18 | 15 | -3.7 | -52 | 15 | 22 | -28 | -8.1 | -2.5 | -9.4 | -3.2 | -4.7 | -6.6 | 11 | 1.1 | -12 | -0.1 | -3.6 | -10 | -23 | -0.1 | -47 | -80 | |
| 0.5 | 2.7 | 4.1 | 2.3 | 0.9 | 2.4 | 1.0 | 2.7 | 1.8 | 8.7 | 5.6 | 12 | 5.3 | 3.7 | 0.9 | 2.7 | 1.9 | 1.8 | 2.9 | 3.3 | 2.9 | 5.9 | 4.2 | 0.8 | 0.2 | 0.5 | 0.4 | 0.2 | 0.0 | 0.2 | 0.2 | 0.2 | 0.7 | 0.5 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.3 | |
| 28 | -142 | -13 | 42 | -81 | 23 | 48 | -894 | -621 | 88 | -12 | 25 | 58 | 135 | 198 | 157 | 49 | 93 | 10 | 73 | -0.8 | 120 | 130 | 84 | 111 | 40 | 41 | 25 | 56 | 17 | 19 | 17 | 46 | 60 | 44 | 50 | -95 | 0.4 | -351 | -399 | -844 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 8.4 | 192 | 12 | 10 | 10 | 27 | 34 | 811 | 3.9 | 2.7 | 4.9 | 7.3 | 6.2 | 4.9 | 11 | 8.0 | 1.5 | 2.7 | 17 | 11 | 2.9 | 1.8 | 0.2 | 0.5 | – | – | 0.0 | 0.0 | 0.0 | – | -3.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | |
| -1.9 | -0.6 | -0.6 | -0.8 | -0.8 | -3.0 | – | – | – | – | – | – | -250 | -250 | -250 | -250 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 6.5 | 191 | 11 | 9.5 | 9.5 | 24 | 34 | 811 | 3.9 | 2.7 | 4.9 | 7.3 | 6.2 | 4.9 | 11 | -242 | 1.5 | 149 | 18 | 12 | 3.7 | 2.6 | 0.9 | 0.5 | 0.1 | 0.1 | 0.0 | 0.0 | -65 | 0.0 | 42 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 142 | 39 | 530 | 365 | 1,074 | |
| 7.6 | -3.7 | -36 | -7.3 | 22 | -33 | 30 | 876 | -689 | -27 | -88 | -21 | -4.2 | 15 | 131 | -169 | -2.9 | 142 | -47 | -128 | 40 | -40 | 43 | 11 | 28 | -23 | -11 | -26 | 14 | -30 | 15 | -21 | 2.1 | 14 | -5.4 | 4.1 | -2.0 | -1.2 | 129 | -110 | 15 | |
| -28 | -55 | -39 | -61 | 92 | -83 | -53 | 957 | -73 | -126 | -87 | -66 | -74 | -129 | -79 | -87 | -55 | -100 | -80 | -86 | -104 | -157 | -93 | -76 | -83 | -58 | -52 | -52 | -42 | -47 | -48 | -38 | -45 | -47 | -49 | -46 | -49 | -65 | -44 | -76 | -234 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.